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Cutaneous T cell lymphomas are a clonal prolifer-
ation of CD4+ T lymphocytes primarily involving
the skin. Mycosis fungoides is an epidermotropic
CD4+ cutaneous T cell lymphoma, and a more
aggressive form, Sezary syndrome, occurs when the
malignant cells become nonepidermotropic. The
role of neuropeptides in the growth and chemotaxis
capacity of cutaneous T cell lymphoma cells remains
unknown. In this report, we found that cutaneous T
cell lymphoma cells, similarly to normal resting or
activated peripheral lymphocytes, were able to bind
neurotensin. We used an interleukin-2-dependent
cutaneous T cell lymphoma malignant T cell line
derived from cutaneous T cell lymphoma lesions in
order to study the role of neurotensin in the prolifer-
ation and migration of these malignant cells. First,
we determined that the malignant cells expressed
neurotensin receptors on their cell membrane.
Functional results indicated that neurotensin did not
stimulate the growth of the cell line. In contrast, this
neuropeptide inhibited the proliferation of the tumor
cells in response to exogenous interleukin-2.
Furthermore, we found that neurotensin enhanced
both spontaneous and chemoattractant-induced
migration of the malignant cells. This suggests that
neurotensin in skin can play a role in the disease by
locally limiting the growth of the cutaneous T cell
lymphoma tumor cells in response to cytokines and
by enhancing their chemotaxis capacity. Key words:
neuropeptides/neurotensin receptor antagonist/T lymphocyte
migration. J Invest Dermatol 117:687±693, 2001
I
t is now well established that nervous, endocrine, and
immune systems constitute a totally interconnected circuit
via hormones and neuropeptides (Besedovsky et al, 1985;
Savino and Dardenne, 1995). All lymphoid organs and
tissues receive innervation by ®bers containing a varied
spectrum of peptides including tachykinins, calcitonin gene-related
peptide (CGRP), somatostatin (SOM), vasoactive intestinal peptide
(VIP), and neurotensin (NT) (Felten et al, 1985; Misery, 1997).
Recent observations suggest that these neuropeptides are able to
regulate a cutaneous in¯ammatory process (Ansel et al, 1997;
Lambert and Granstein, 1998). Further, it was found that cutaneous
cells secreted these neuropeptides and expressed their speci®c
receptors (Lotti et al, 1995; Gaudillere et al, 1999). Immune cells
present in the skin are modulated by neuropeptides through a
speci®c receptor (Staniek et al, 1995). In this context, several
neuropeptides have been reported to modulate the immune
responses in the peripheral system (De la Fuente et al, 1998;
Delgado et al, 1999) and in the skin (Hosoi et al, 1993; Scholzen et
al, 1998). NT is a tridecapeptide ELYENKPRRPYIL, which has
been reported to modulate cell functions of both innate and
adaptive immunity (Goldman et al, 1982; Koff and Dunegean,
1985; Lemaire, 1988; Garrido et al, 1992; De la Fuente et al, 1993;
Evers et al, 1994; Lhiaubet et al, 1998). It was originally isolated
from bovine hypothalami (Carraway and Leeman, 1973) and is
distributed in the central and peripheral nervous systems and
gastrointestinal tract (Carraway and Leeman, 1976; Reinecke,
1985). In the gut, NT is localized to specialized enteroendocrine
cells (N cells) of the distal small bowel mucosa. NT receptor has
been characterized pharmacologically and the cDNA was cloned
from rat brain (Tanaka et al, 1990) and from the human colonic
adenocarcinoma cell line HT29 (Vita et al, 1993). This NT
receptor, however, now referred to as NT1 receptor, which was
found in various human colon cancer cell lines, is not expressed in
normal colonic epithelium (Maoret et al, 1994). A second NT
receptor, NT2 receptor, has been isolated from human hypotha-
lami. Interestingly, it has been found that triggering NT2 receptor
by NT does not induce biologic responses, whereas nonpeptide
NT1 receptor antagonists are potent agonists (Chalon et al, 1996;
Vita et al, 1998). Both receptors belong to the G-protein-coupled
receptor family. Recently, the gp95/sortilin has also been found to
bind NT; however, this receptor is structurally different from the
other two G-protein-coupled NT receptors, as it is similar to the
mannose 6-phosphate receptor bearing a single transmembrane
domain (Mazella et al, 1998).
In this study we investigate the role of NT in the growth and
migration of cutaneous T cell lymphoma (CTCL) malignant cells.
CTCL are clonal proliferations of CD4+ T lymphocytes that
include mycosis fungoides and its leukemic variant, Sezary
syndrome (Sterry and Mielke, 1989; Willemze et al, 1997). We
report here that both freshly isolated CTCL malignant cells and
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long-term cultured cytokine-dependent CTCL cell lines (Bagot et
al, 1998; Echchakir et al, 2000; Poszepczynska et al, 2000) are
binding to NT. As it is dif®cult to distinguish the malignant T
lymphocytes from normal reactive T lymphocytes, which also bind
NT in cutaneous lesions or in peripheral blood from Sezary
patients, we used our unique cytokine-dependent CTCL cell lines
for this study. We found that NT1 but not NT2 receptors were
expressed by these CTCL lines. Functional results indicated that
NT at low physiologic concentrations inhibited the growth of a
CTCL line induced by recombinant interleukin-2 (IL-2).
Surprisingly, we found that the selective nonpeptide NT antagonist
of NT1 receptor, SR48692 (Gully et al, 1993; Oury-Donat et al,
1995; Iwase et al, 1997), enhanced the binding of NT in CTCL and
potentialized its inhibitory effect. The results suggested that these
effects might be mediated by a stabilization of NT receptors at the
cell surface and/or by a rapid recovery due to the stabilization of
internalized NT receptors (Hermans and Maloteaux, 1998; Mazella
et al, 1998; Morello et al, 2000). Interestingly, we found that NT
increased both spontaneous migration and chemoattractant agent-
induced migration of CTCL. In conclusion, these data demon-
strated that NT binds to the functional receptor known as NT1
receptor on CTCL cells and that it can play a role in the
progression of the disease by down-modulating tumor cell
proliferation and enhancing their migration.
MATERIALS AND METHODS
Patients After informed consent and approval of an ethics committee
(CCPPRB, HoÃpital Henri Mondor, CreÂteil, France), we took skin
fragments and/or blood samples from six patients with a CTCL
including three with Sezary syndrome. Two different patients presented
with a transformed mycosis fungoides. Histologic examination of the
patients showed an epidermotropic skin in®ltrate composed of
CD3+ CD4+ CD8± atypical lymphocytes as determined by their
cytologic aspect. One patient, named Pno, had a 10 y history of
generalized erythrodermia. Skin and peripheral blood contained CD3+
TCRVb22+ CD4+ CD8+ atypical lymphocytes (Poszepczynska et al,
2000; 2001). Blood from patients with Sezary syndrome, which were
invaded with more than 80% of CD3+ CD4+ tumor cells, were used
for the phenotypic analysis. None of the patients had been previously
treated with chemotherapy.
Isolation of tumoral lymphocytes Fresh CTCL tumor cells were
obtained from skin fragments mechanically dispersed into single-cell
suspensions, as previously described (Bagot et al, 1998). The
mononuclear cells were then washed and frozen in human serum plus
10% dimethyl sulfoxide for later use.
Tumor cell lines We established the Pno cell line (TCRVb22+,
CD4+, CD8aa+) in vitro from the peripheral blood of the patient, as
reported elsewhere (Poszepczynska et al, 2000). Brie¯y, mononuclear
cells were isolated by the technique of Ficoll-Isopaque (Pharmacia Fine
Chemicals, Piscataway, NJ) density gradient centrifugation. Cells were
cultured in culture medium consisting of RPMI 1640 (Gibco, Paisley,
U.K.), 2 mmol per liter L-glutamine, penicillin (100 U per ml),
streptomycin (100 mg per ml), 10% heat-inactivated human serum, and
IL-7 (10 ng per ml, produced by Sano®-SyntheÂlabo Recherche, LabeÁge,
France). Lymphocyte expansion was performed by plating cells into
round-bottomed 96-well plates (Greiner, NuÈrtingen, Germany). The
®nal volume in each well was 200 ml of culture medium. Every 2 d fresh
culture medium was added to the wells, and the cells were collected
each week. We demonstrated that both the malignant clone circulating
in the patient's blood and the derived cultured T cell line were identical,
as they shared the same size and sequence of the T cell receptor b
(TCR-b) VDJ region and exhibited similar functional properties
(Poszepczynska et al, 2000). The Cou-L malignant cell line
(TCRVb13+, CD4+, CD8±) is a subclone of the cell line Cou-LS,
which was obtained from the skin of a patient and has been cultured
in vitro with recombinant IL-2 for more than 3 y (Bagot et al, 1998;
Echchakir et al, 2000).
Reagents Fluorescein isothiocyanate (FITC) conjugated NT (NT-
FITC) was purchased from Advanced Bioconcept (Montreal, Canada).
NT was obtained from Sigma (Saint Quentin Fallavier, France) and was
prepared as 1 mM stock solutions. The nonpeptide NT1 receptor
antagonist SR48692 was dissolved at 1 mM in dimethylsulfoxide (Gully
et al, 1993). Both the NT and the SR48692 were stored at ±20°C in
50 ml aliquots. IL-7 (10 ng per ml) and IL-2 (50 U per ml) were
produced by Sano®-SyntheÂlabo Recherche. The monoclonal antibody
B-N6 recognizing NT1 receptors (Ovigne et al, 1998) was kindly
provided by Dr. J. Wijdenes from Diaclone, BesancËon, France.
Conjugated anti-TCR-Vb monoclonal antibodies were purchased from
Immunotech-Coulter (Marseille, France).
Cells Peripheral blood mononuclear cells from normal individuals
were isolated by the technique of Ficoll-Isopaque (Pharmacia Fine
Chemicals) density gradient centrifugation. Activated peripheral blood
lymphocytes (PBL) were obtained by culturing cells for 3 d in 24-well
tissue culture plates at a concentration of 105 cells per ml in RPMI 1640
medium containing 10% heat-inactivated human serum and 1 mg per ml
of phytohemagglutinin (PHA; Wellcome, Beckenham, U.K.). Chinese
hamster ovary (CHO) cells expressing high levels of NT receptors 1
were obtained and cultured as previously described (Vita et al, 1993).
Immuno¯uorescence staining Adherent cell lines were treated with
5 ml of ethylenediamine tetraacetic acid 0.02% per 175 cm2 culture ¯ask
for 10 min at 37°C and washed with phosphate-buffered saline and 1%
bovine serum albumin (PBS±1% BSA). Non-adherent cells were
harvested by centrifugation and washed with PBS±1% BSA. 2 3 105
cells (100 ml) were incubated for 20 min at 4°C with 50 ml of 100 nM
NT-FITC in PBS±1% BSA. Nonspeci®c NT binding was determined by
incubating cells with NT-FITC in the presence of 100-fold excess of
nonconjugated NT provided by the manufacturer. After washing the
cells in PBS, they were analyzed by ¯ow cytometry using a single argon
¯ow cytometer analyzer (Epics XL, Beckman-Coulter, Miami, FL).
Indirect immuno¯uorescence analysis with B-N6 antibodies was
performed by incubating 2 3 105 cells with the speci®c antibody for
30 min at 4°C, subsequent washing, and incubation with FITC-
conjugated af®nity-puri®ed goat antimouse Ig for an additional 30 min at
4°C. Cells were then extensively washed before ¯ow cytometric analysis.
Isotype control monoclonal antibodies were used to establish the PMT
settings. For two-color analysis the immuno¯uorescent staining was
performed by incubating 3 3 105 cells with phycoerythrin-conjugated
anti-TCR-Vb antibodies and NT-FITC for 30 min at 4°C. Flow
cytometry analysis of the samples was done on gated lymphocytes.
Proliferation assays Triplicate cultures of cells (5 3 104 per well),
with or without NT (10±6±10±9 M), in a ®nal volume of 0.2 ml in 96-
well round-bottomed plates were cultured with 50 U per ml of IL-2.
The proliferative responses of the Cou-L cells to various concentrations
of NT and to nonpeptide NT analog SR48692 were determined by
measuring the [3H]-thymidine incorporation (cpm). After 60 h of
culture, tritiated thymidine (1 mCi) was added to each culture well and
incubation was continued for an additional 18 h. Incorporation of
tritiated thymidine was measured in a microplate scintillation counter
(Topcount, Packard Instrument, Meriden, CT). The percentage of
inhibition was calculated using the equation 1 ± cpm obtained from
culture of malignant cells proliferating to IL-2 (50 U per ml) with NT
(1000 nM) alone or with NT (1000 nM) + various concentrations of
SR48692 divided by cpm obtained from control culture of malignant
cells proliferating to IL-2 (50 U per ml).
Assay of spontaneous mobility and chemotaxis Spontaneous
mobility and chemotaxis were evaluated according to a modi®cation of
the original technique described by Boyden (1962). Brie¯y, we used 24-
well chambers with two compartments separated by a ®lter of 5 mm pore
size (Costar, Corning, NY). Aliquots of 20 ml of cell suspensions (5 3
106 cells per ml) were deposited in the upper compartment with 80 ml
of NT at ®nal concentrations ranging from 1 nM to 1000 nM, or 80 ml
of culture medium. Aliquots of 600 ml of a chemoattractant agent, N-
formyl-Met-Leu-Phe (10±7 M), or medium were placed in the lower
compartment of the chamber for chemotaxis or spontaneous mobility
assays, respectively. The chambers were incubated at 37°C for 12 h. Cell
migration was estimated by counting the total number of viable cells
migrating in the lower compartments. The cell viability was determined
using trypan blue exclusion.
Polymerase chain reaction (PCR) experiment Total RNA was
extracted from different areas of human brain and from Cou-L cells (5 3
106) using the acid guanidinium isothiocyanate phenol chloroform
method (RNAzol B method). cDNA was prepared by a standard method
using reverse transcriptase and oligo-dT primer. PCR was performed
with two hNT1 receptor speci®c primers at position 2216 (backward: 5¢-
GGG-CCC-CCA-GCT-TGC-CAG-3¢) and 1413 (forward: 5¢-GGT-
GAC-CAA-CGC-ACT-CTT-3¢) giving a PCR product of 803 bp. For
the PCR for hNT2 receptor, the primers at position 1270 (backward: 5¢-
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TCA-GGT-CCG-GGT-TTC-TGG-G-3¢) and 760 (forward: 5¢-CTG-
GCC-CTC-TGC-TCC-CAA-3¢) were used and gave a product of
510 bp. The reaction cycle consisted of denaturation for 1 min at 94°C,
annealing for 1 min at 55°C, and extension for 1 min at 72°C, and was
repeated 35 times.
Statistical analysis All values are expressed as the mean of cpm 6
standard deviation or the mean of lymphocyte number 6 standard
deviation. The data were evaluated statistically using ANOVA followed
by the posthoc Dunnett test. Differences were considered signi®cant when
p-values were < 0.01.
RESULTS
Expression of the NT receptor on normal and CTCL
malignant lymphocytes The ability of NT to bind normal
and malignant lymphocytes was determined by ¯ow cytometry
with NT directly conjugated to FITC (NT-FITC). We tested as
control whether CHO cells, which expressed high amounts of
recombinant NT receptors 1 (CHO-NT1 receptor), were able to
bind NT-FITC. We found that CHO-NT1 receptor bound
speci®cally NT-FITC (Fig 1B). Negative controls (shaded
histograms) were obtained with an excess of unlabeled NT
(according to the manufacturer's recommendations). The
concentration of NT-FITC used for further ¯ow cytometry
studies was that which gave the highest speci®c maximum mean
¯uorescence intensity with CHO-NT1 receptor and which
simultaneously gave minimal auto¯uorescence with CHO mock
cells (Fig 1A). Next, we analyzed the staining of normal PBL with
NT-FITC and compared the mean ¯uorescence intensity obtained
with resting and PHA-activated PBL gated lymphocytes. The
results presented in Fig 1(C) indicate that PBL were weakly
stained, whereas the same cells once activated with PHA increased
their speci®c binding to NT-FITC. Interestingly, lymphocytes
isolated from a tumoral skin fragment that contained a majority of
malignant T lymphocytes were able to bind NT-FITC (Fig 1D).
Further, we studied two long-term cultured CTCL lines for their
reactivity with NT-FITC. The results revealed that both CTCL
cell lines were stained with a signi®cant mean ¯uorescence intensity
(Fig 1E, F). Finally, to demonstrate that freshly isolated CTCL
malignant cells were able to bind NT, we tested the blood of three
different Sezary syndrome patients. We found that the tumor cells
that were identi®ed using anti-TCR-Vb monoclonal antibodies
were signi®cantly reactive with NT-FITC (Fig 2).
Expression of NT1 receptors on the CTCL cloned cell line
Cou-L To further demonstrate the expression of NT receptors
and to determine whether CTCL malignant cells expressed NT1
receptors or NT2 receptors or both, with the malignant CTCL
Cou-L cell line we performed reverse transcriptase PCR analysis of
NT receptor mRNA using speci®c oligonucleotide primers. The
results presented in Fig 3(A) reveal a single PCR product of the
expected size (786 bp) corresponding to NT1 receptors. The
presence of NT1 receptors was also detected in the brain (used as
control). In contrast, using the speci®c NT2 receptor
oligonucleotide primers the Cou-L line failed to express a PCR
product of the expected size (510 bp) (data not shown).
Interestingly, we further demonstrated the expression of NT1
receptors on Cou-L cells with the anti-NT1 receptor monoclonal
antibody termed B-N6. The results presented in Fig 3(B) indicate
that B-N6 monoclonal antibody stained Cou-L cells. Overall, these
results clearly indicate that Cou-L expressed the NT1 receptors but
not the NT2 receptors.
Inhibitory effect of NT on Cou-L cell proliferation We next
examined the effect of NT on the IL-2-dependent malignant Cou-
L cells. We found that various concentrations of NT were unable to
induce the proliferation of Cou-L cells in the absence of IL-2 (data
not shown). We then tested the effect of NT on IL-2-induced
Cou-L cell proliferation. Figure 4(A) shows that the maximun
proliferation of Cou-L T lymphocytes was reached with 50 U per
ml of IL-2. Therefore, we studied the effect of various
concentrations of NT on the Cou-L lymphocyte proliferation
Figure 1. Flow cytometric analysis of NT-FITC binding to various cells. NT-FITC (100 nM) was incubated for 20 min at 4°C with 2 3 105
(A) CHO cells; (B) CHO-hNT1R; (C) PBL and PHA-activated PBL; (D) CTCL cells freshly isolated from the tumoral skin fragments of patient Cou
(Bagot et al, 1998); (E) CTCL malignant cell line Pno; or (F) CTCL malignant cell line Cou-L. Non-speci®c NT binding (shaded histograms) was
determined by incubating NT-FITC with 100-fold excess nonconjugated NT. The relative cell number (ordinate) was plotted against the ¯uorescence
intensity of the bound reagent (abscissa, log scale). These results are representative of six independent experiments.
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induced with 50 U per ml of IL-2. The results presented in
Fig 4(B) indicate that NT induced a strong inhibition of IL-2-
induced Cou-L proliferation. A signi®cant inhibitory effect was
obtained with various concentrations of NT, starting from 200 nM.
No toxic effect of NT was observed, as various control cultures of
Cou-L with 1000 nM of NT and IL-2 did not affect the viability of
the cells (data not shown).
Effect of the NT1 receptor antagonist SR48692 on NT-
induced inhibition of Cou-L proliferation In order to
neutralize the effect of NT on the IL-2-induced proliferation of
Cou-L cells, we used the nonpeptide NT1 receptor antagonist
SR48692. We found that SR48692 alone used at various
concentrations had no effect on IL-2-induced Cou-L cell
proliferation (Fig 5A). Surprisingly, when both NT and
SR48692 were used a signi®cant enhancement of the inhibition
was obtained compared to the inhibition with NT alone (Fig 5B).
NT (1000 nM) with 800 or 1000 nM of SR48692 was able to
inhibit 80% of the Cou-L proliferation obtained with IL-2 alone,
whereas the same concentration of NT alone gave 50% inhibition.
In order to determine the mechanism by which NT and SR48692
exerted a synergic effect on the inhibition of the IL-2-induced
malignant cell proliferation, we analyzed by ¯ow cytometry the
binding of NT-FITC to Cou-L cells after incubation with
1000 nM of SR48692. The results shown in Fig 6 indicate that
pretreatment of Cou-L cells with SR48692 resulted in an
enhancement of the percentage of positive cells as well as an
increase in the mean ¯uorescence intensity. As control, under the
same experimental conditions, the SR48692, which was previously
Figure 2. Expression of NT receptor on fresh circulating Sezary
syndrome malignant cells. We performed two-color ¯ow cytometric
analysis using phycoerythrin-conjugated anti-TCR-Vb antibodies and
NT-FITC. Cells were incubated with both reagents for 30 min at 4°C
and washed with PBS±1% BSA before ¯ow cytometric analysis. The
three different patients were selected for phenotypic analysis as their
blood was invaded with a majority of malignant cells, which could be
identi®ed by speci®c anti-TCR-Vb antibodies. Right panels correspond
to single-color ¯ow cytometric analysis using NT-FITC. Nonspeci®c
NT binding (shaded histograms) was determined by incubating cells with
NT-FITC in the presence of 100-fold excess nonconjugated NT.
Figure 3. RT-PCR and ¯ow cytometric analysis of the NT1
receptor in Cou-L malignant cell line. (A) RNA extracted from
Cou-L cells and brain (positive control) were reverse-transcribed into
cDNA. Then ampli®cation was performed using NT1 receptor primers.
The speci®c PCR product of the expected size of 786 bp is indicated by
an arrow. (B) Cou-L cells were incubated with B-N6 (ascites diluted
1:100) for 30 min at 4°C and then washed with PBS±1% BSA. For
indirect immuno¯uorescence analysis the cells were further incubated
with FITC-conjugated af®nity-puri®ed goat antimouse IgM as described
in Materials and Methods. The shaded histogram represents the labeling with
an irrelevant control monoclonal antibody.
Figure 4. Modulation of IL-2-dependent Cou-L cell proliferation
by NT. (A) Cou-L cells were cultured with various concentrations of
IL-2 as described in Materials and Methods. The proliferation reached a
plateau with 50 U per ml of IL-2. (B) Various concentrations of NT
were added to Cou-L cells that were driven into proliferation with 50 U
per ml of IL-2. The results represent the mean cpm 6 SD of eight
separate experiments performed in triplicate; *p < 0.01 with respect to
control values obtained in the absence of NT.
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reported to bind CHO cells expressing the NT1 receptors, reduced
signi®cantly the labeling that was obtained with NT-FITC.
Effect of NT on the spontaneous mobility and chemotaxis of
Cou-L cells We next studied the effect of NT on the mobility
and the chemotaxis induced by N-formyl-Met-Leu-Phe as
chemoattractant. The presence of NT in the upper compartment
of the Boyden chambers signi®cantly increased the spontaneous
mobility (Fig 7). The more ef®cient concentrations were 100±
500 nM of NT. Further, when 10±7 M of N-formyl-Met-Leu-Phe
was added in the lower chamber, we obtained a stimulation of the
chemotaxis capacity of the malignant lymphocytes that was
signi®cantly increased with 200 and 500 mM of NT.
DISCUSSION
NT has been reported to modulate immune responses, including
PBL proliferation (Johansson and Sandberg, 1989; Evers et al,
1994). Functional NT receptors have been described in various
human tumor cell lines derived from colonic adenocarcinomas
(Amar et al, 1986; Iwase et al, 1996; Ehlers et al, 1998), small cell
lung carcinomas (Woll and Rozengurt, 1989), prostate adenocar-
cinomas (Carraway and Mitra, 1998; Mitra and Carraway, 1999),
and leukemias (Choi et al, 1999). In this study, we report for the
®rst time the NT receptor expression on freshly isolated CTCL
malignant cells and CTCL malignant cell lines, which were derived
from lesional skin (Cou-L) or peripheral blood of patients with
Sezary syndrome (Pno). Flow cytometry analysis with NT-FITC
indicated that normal resting and PHA-activated PBL, freshly
isolated CTCL cells, and CTCL lines were capable of binding
speci®cally NT. We found, however, that levels of NT binding in
normal activated PBL were greater than those found in freshly
isolated PBL. Previous studies have reported the presence of
binding sites with different af®nities for NT on human PBL.
Scatchard analysis of NT binding to PBL suggested the existence of
two types of binding sites with different af®nities (Evers et al, 1994).
Our results obtained by ¯ow cytometry analysis were unable to
distinguish these two classes of binding sites, as we consistently
obtained a homogeneous weak pro®le with a unique peak. We
found that CTCL cell lines, which were maintained in culture with
cytokines, were capable of binding NT. Thus, they do not differ
from leukemic T cell lines such as Jurkat or Molt-4, which have
already been reported to express NT receptors using a combination
of molecular techniques and Scatchard analysis (Evers et al, 1994).
Functional studies revealed that NT inhibited the proliferation of
the CTCL Cou-L cell line in response to IL-2. The maximum
effect was observed in the same dose range at which NT has been
reported to exert biologic effects in other systems (Evers et al, 1994;
Ehlers et al, 1998; Choi et al, 1999). The inhibition was speci®c,
and mediated through the NT1 receptor. Interestingly, we were
able to detect B-N6 monoclonal antibody binding by ¯ow
cytometry on Cou-L malignant cells. This monoclonal antibody
was previously reported to bind speci®cally to hNT1 receptor but
not to hNT2 receptor transfected CHO cells (Ovigne et al, 1998).
The NT1 receptor in human tissues is a 418 amino acid protein that
belongs to the family of G-protein-coupled receptors with seven
Figure 5. The nonpeptide NT1 receptor antagonist SR48692
potentialized the inhibitory effect of NT in Cou-L malignant
cells. (A) Various concentrations of SR48692 or NT were added to
Cou-L cells proliferating in response to 50 U per ml of IL-2. The results
represent the mean cpm 6 SD of ®ve separate experiments performed in
triplicate; *p < 0.01 with respect to control values obtained in the
absence of NT. (B) Various concentrations of SR48692 were added to a
unique concentration of NT (1000 nM) in the culture wells containing
Cou-L cells stimulated with 50 U per ml of IL-2. The percentage
inhibition was calculated as indicated in Materials and Methods. The results
represent the mean cpm 6 SD of three separate experiments performed
in triplicate; *p < 0.01 with respect to control values obtained in the
presence of NT alone.
Figure 6. Flow cytometric analysis of NT-FITC binding to
CHO-NT1 receptor and Cou-L after pretreatment with the
nonpeptide NT receptor antagonist SR48692. (A) CHO-hNT1R
and (B) Cou-L cells were incubated with 1000 nM of SR48692 for
30 min before the addition of 100 nM of NT-FITC. The cells were
incubated for 20 min at 4°C, washed, and resuspended in PBS for
analysis by ¯ow cytometry.
Figure 7. In¯uence of various concentrations of NT on the
spontaneous mobility and on chemotaxis of Cou-L malignant
cells. The results represent the mean 6 SD of three separate
experiments performed in duplicate; *p < 0.01 with respect to control
values obtained in the absence of NT.
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transmembrane spanning domains connected by intracellular and
extracellular loops, and its mRNA is expressed normally in the
brain and peripheral systems. The inhibitory effect of NT on IL-2-
induced Cou-L cell proliferation was unexpected as a previous
report indicated that NT signi®cantly enhanced PHA-stimulated
PBL proliferation (Evers et al, 1994). These contradictory results are
probably only apparent, however, as PBL, which proliferate to
PHA, and Cou-L cells, which proliferate to exogenous Il-2, are
differently triggered into proliferation, and they also differ in their
cell activation status. Our ®nding is further supported by the
functional consequences of the triggering of the G-protein-coupled
bombesin receptors expressed on the murine IL-2-dependent T cell
line CTLL-2. It was reported that the speci®c tetradecapeptide
inhibits the IL-2-induced proliferation of the murine cell line
(Ehrhardt and Dancygier, 1988). IL-2 is the critical growth factor
for the clonal expansion of antigen-speci®c T lymphocytes.
Molecules that modify cell responsiveness to IL-2 may therefore
prove important in the future, either for our understanding of the
physiologic regulation of immune functions or for their pharma-
cologic modulation. The molecular mechanisms involved in the
negative signal provided through NT receptors to the IL-2
intracellular signaling in Cou-L malignant cells are unknown.
Recent reports, however, indicated that IL-2 in T lymphocytes
induces tyrosine phosphorylation of the focal adhesion kinase-
related protein B (FAK, pp125FAK) only in cells expressing the
integrin b2 subunit CD18 (Brockdorff et al, 1998; Rodriguez-
Fernandez et al, 1999). Interestingly, bombesin was also found to
stimulate pp125FAK in human prostate carcinoma PC-3 cells
(Duncan et al, 1996). Thus, it will be important to study the
recruitment of pp125FAK in CD18 molecules expressing Cou-L
malignant cells stimulated by both NT and IL-2. A direct effect of
NT on IL-2 receptor expression seems unlikely, as we found that
short-time cultures of Cou-L cells with 1 mM of NT did not alter
the level of CD25, CD122, and CD132 molecules analyzed by
¯ow cytometry (data not shown). We next demonstrated that the
NT receptor antagonist SR48692 alone did not affect cell
proliferation. Surprisingly, pretreatment of the cells with
SR48692 before addition of NT signi®cantly increased the
inhibition of cell proliferation obtained with NT alone. SR48692
competed with NT not only in NT-receptor-transfected-CHO
cells but also in other human cell lines that expressed NT1 receptors
(Oury-Donat et al, 1995). Thus, it was found in these malignant cell
lines that SR48692 completely displaced NT from its receptor and
fully antagonized the intracellular events induced by NT. In
contrast, with the Cou-L cell line we found that preincubation
with 1 mM of SR48692 led to an important increase in NT
binding. Various hypotheses can be proposed to explain these
results: one of these could be that SR48682 binding stabilized
intracellular NT receptors and therefore induced a rapid recovery
of these receptors. To support this hypothesis, recent results have
demonstrated that nonpeptidic V2 vasopressin receptor antagonists
were capable of rescuing cell surface expression and function of
misfolded receptors (Morello et al, 2000). Further studies are
needed to verify this hypothesis and to explain the results obtained
with SR48692 in Cou-L cells.
We next studied whether interaction of NT with its own
receptor in Cou-L cells might act on cellular migration. We found
that NT stimulated the mobility and the chemotaxis of the
malignant cells. Interestingly, previous reports have indicated that
NT stimulates the adherence and the chemotaxis capacities of
normal murine peritoneal lymphocytes (Garrido et al, 1992).
Therefore, the human malignant CTCL cells behave like normal
lymphocytes with regard to the stimulation of chemotaxis capacity
by NT. It must be noted that the induction of lymphocyte
migration by NT was also obtained with other neuropeptides such
as VIP (Johnston et al, 1994). Interestingly, the tyrosine phos-
phorylation of pp125FAK was found to be decisive in the regulation
of spontaneous T lymphocyte locomotion (Entschladen et al, 1997).
Further, the migration induced by pp125FAK was directionally
persistent and involved extensive organization of actin micro®la-
ments and focal adhesions (Gu et al, 1999). Thus, further studies are
needed to demonstrate that NT is involved in pp125FAK recruit-
ment and that this tyrosine kinase plays a crucial role in the
proliferation and migration of the CTCL cells. Elucidation at the
molecular level of the intracellular pathways that are involved
during the CTCL malignant cell proliferation or migration process
will lead to a better understanding of the evolution of this disease. It
remains also to demonstrate with in vivo studies that NT could
stimulate the migration of the integrin b2 subunit expressing
CTCL malignant cell lines. Such a property of NT on CTCL
malignant cell migration needs also to be demonstrated with other
tumor cells as it has been reported recently that nude mice, which
had been xenografted with human colon cancer cells and treated
with NT, failed to exhibit metastatic sites of tumor development
(Maoret et al, 1999).
In conclusion, we demonstrate the expression of NT1 receptors
by human CTCL cells. These receptors are functional and have
signi®cant immunoregulatory properties for the malignant lym-
phocytes. These ®ndings may have important implications in the
development of novel therapeutic strategies for treating human
CTCL expressing NT receptors. Further studies are needed,
however, to determine whether NT is involved in the physio-
pathology of this disease before starting to use NT or NT antagonist
as therapeutic agents (Witzig et al, 1995).
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